Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,584 matching trials from the live ClinicalTrials.gov search.
Conditions
Cancer
Interventions
Dabrafenib, Trametinib, Panitumumab, 5-fluorouracil
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Prescription Opioid Misuse: ROPEs Pilot Trial

NCT03691948
Conditions
Knowledge, Attitudes, Practice
Interventions
Responsible Opioid Prescriber Education (ROPES), Active Comparator Control
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product.

NCT03617926
Conditions
Head Lice, Pediculosis Capitis
Interventions
X92001666, RID shampoo
Device · Other
Lead sponsor
Oystershell NV
Industry
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Plantation, Florida
Conditions
Hypertension
Interventions
CTC Intervention, Control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Bedford, Massachusetts • Philadelphia, Pennsylvania
Conditions
Thromboembolism
Interventions
IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
Genetic · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
66
States / cities
Daphne, Alabama • Springdale, Arkansas • Duarte, California + 57 more
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Conditions
Epilepsy, Sleep Apnea, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), Placebo-CPAP
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
4
States / cities
Ann Arbor, Michigan • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
Conditions
Hemiparesis
Interventions
Mental Practice Group, Active Control Group
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • Columbus, Ohio
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

NCT01399008
Conditions
Gout
Interventions
Arhalofenate, Allopurinol, Colchicine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
16
States / cities
Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study of AP0302 5% Versus a Vehicle Comparator

NCT02324985
Conditions
Pain, Delayed Onset Muscle Soreness
Interventions
S-Ibuprofen Topical Gel 5%, Vehicle Topical Gel
Drug
Lead sponsor
Aponia Laboratories, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pasadena, California
Conditions
Epilepsies, Partial
Interventions
Lyrica (pregabalin), placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
103
States / cities
Mobile, Alabama • Northport, Alabama • Tuscaloosa, Alabama + 57 more
Conditions
COPD
Interventions
Umeclidinium / Vilanterol Dry Powder Inhaler, Placebo
Drug
Lead sponsor
Gary L. Pierce
Other
Eligibility
30 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Sham Intervention, Survey Administration, Transcranial Direct Current Stimulation
Procedure · Other · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Covid19
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
93
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 81 more
Conditions
Sudden Cardiac Death, Ventricular Arrythmias
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Aspirus Heart and Vascular Institute-Research and Education
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wausau, Wisconsin
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile Attention Retraining in Overweight Female Adolescents

NCT02977403
Conditions
Obesity, Overweight, Binge Eating, Healthy Volunteers
Interventions
Attention Bias Retraining, Sham Comparator: AB Control
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 21 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions
Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
Other · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Non Small Cell Lung Cancer
Interventions
Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), 18 F fluorodeoxyglucose
Radiation
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Coral Gables, Florida • Decatur, Illinois • Baltimore, Maryland + 2 more
Conditions
Alzheimer Disease
Interventions
AMX0035, Placebo
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Jacksonville, Florida • Orlando, Florida • Palmetto Bay, Florida + 7 more
Conditions
Sleep Apnea Syndromes
Interventions
Self-management, Telemonitored care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Diego, California
Completed Not applicable Interventional Results available

Randomized Controlled Trial of CES for Fibromyalgia

NCT04115033
Conditions
Fibromyalgia
Interventions
Alpha-stim
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Completed Phase 4 Interventional Results available

Phase IV O2 Consumption Study in COPD Patients.

NCT02533505
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol, Matching Placebo pMDI 160/4.5 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Hartford, Connecticut • Boston, Massachusetts • Charlotte, North Carolina + 2 more
Conditions
Photoaging, Wrinkle, Skin Laxity
Interventions
Hybrid Fractional Laser, Facial Cleanser, Facial Moisturizer, Sunscreen
Procedure · Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Dallas, Texas